


IN THE CLAIMS

1. (currently amended) A compound of formula 1



wherein in which

A is may be nitrogen or an N-oxide group,

B is N-O may be carbon, nitrogen or an N-oxide group,

R¹

(i) is -C₁₋₁₀-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC₆₋₁₄-aryl, -N(C₆₋₁₄-aryl)₂, -N(C₁₋₆-alkyl)(C₆₋₁₄-aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -O-C₆₋₁₄-aryl, -S-C₁₋₆-alkyl, -S-C₆₋₁₄-aryl, -SO₃H, -SO₂C₁₋₆-alkyl, -SO₂C₆₋₁₄-aryl, -OSO₂C₁₋₆-alkyl, -OSO₂C₆₋₁₄-aryl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl, -O(CO)C₁₋₅-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or ~~or~~ and ~~by~~ by a mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycle ~~heterocycles~~ with 5-15 ring members and 1-6 heteroatoms, ~~which are preferably N, O and S,~~

where the C₆₋₁₄-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by at least one of -C₁₋₆-alkyl, -OH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, -SO₃H, -SO₂C₁₋₆-alkyl, -OSO₂C₁₋₆-alkyl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl or ~~or~~ and -O(CO)C₁₋₅-alkyl, and where the alkyl groups on the carbocyclic and heterocyclic substituents in turn may

25664713.1

optionally be substituted one or more times by -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or ~~ex/and~~ -COOH, or

(ii) is -C₂₋₁₀-alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally mono- or polysubstituted by -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC₆₋₁₄-aryl, -N(C₆₋₁₄-aryl)₂, -N(C₁₋₆-alkyl)(C₆₋₁₄-aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -O-C₆₋₁₄-aryl, -S-C₁₋₆-alkyl, -S-C₆₋₁₄-aryl, -SO₃H, -SO₂C₁₋₆-alkyl, -SO₂C₆₋₁₄-aryl, -OSO₂C₁₋₆-alkyl, -OSO₂C₆₋₁₄-aryl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl, -O(CO)C₁₋₅-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, ~~which are preferably N, O and S,~~

where the C₆₋₁₄-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by at least one of -C₁₋₆-alkyl, -OH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, -SO₃H, -SO₂C₁₋₆-alkyl, -OSO₂C₁₋₆-alkyl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl or ex/and -O(CO)C₁₋₅-alkyl,

and where the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by at least one of -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or ex/and -COOH,

R² is hydrogen or -C₁₋₃-alkyl,

R³ and R⁴ may be identical or different and are hydrogen, -C₁₋₆-alkyl, -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -SO₃H, -SO₂-C₁₋₆-alkyl, -COOH, -COO-C₁₋₆-alkyl, -O(CO)-C₁₋₅-alkyl, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₅-alkyl, -phenyl or -pyridyl, where the phenyl or pyridyl substituents in turn may optionally be substituted one or more times by at least one of -C₁₋₃-alkyl, -OH, -SH, -NH₂, -NHC₁₋₃-alkyl, -N(C₁₋₃-alkyl)₂, -NO₂, -CN, -SO₃H, -SO₃C₁₋₃-alkyl, -COOH, -COOC₁₋₃-alkyl, -F, -Cl, -Br, -I, -O-C₁₋₃-alkyl, -S-C₁₋₃-alkyl, or/and -O(CO)C₁₋₃-alkyl, and where the alkyl substituents in turn may optionally be substituted one or

more times by -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H, -SO₃C₁₋₃-alkyl, -COOH, -COOC₁₋₃-alkyl, -O-C₁₋₃-alkyl, -S-C₁₋₃-alkyl or/and -O(CO)-C₁₋₃-alkyl,

or salts of the compounds of formula 1.

2. (previously presented) A compound as claimed in claim 1 having at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (canceled)

4. (currently amended) A compound as claimed in claim 1, wherein R² is -H or -CH₃.

5. (currently amended) A compound as claimed in claim 1 ~~claim 4~~, wherein at least one of R³ and R⁴ is ~~in each case~~ a halogen atom.

6. (currently amended) A compound as claimed in claim ~~4~~ 1, wherein R₂ is ~~-CH₃ A is N-O and B is CH₃, CR³ or N.~~

7. (currently amended) A compound as claimed in claim ~~2~~ 6, wherein R² is -H or -CH₃.

8. (currently amended) A compound as claimed in claim 7, wherein at least one of R³ and R⁴ is ~~in each case~~ a halogen atom.

9. (currently amended) A compound as claimed in claim 1 selected from the group consisting of:

~~N-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

~~N-(2,6-dichlorophenyl)-[1-(2-chlorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

~~N-phenyl-[1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(3-nitrobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

~~N-(3,5-dichloropyridin-4-yl)-[1-(2,4-dichlorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

~~N-(3,5-dichloropyridin-4-yl)-[1-(2-chlorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloropyridin-4-yl)-N-methyl-[1-(2-chlorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-methyl-N-(1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-dichlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-methylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-dimethylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-hexyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-isobutyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-cyclopropylmethyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-naphth-1-yl-methyl]-7-azaindol-3-yl]glyoxylamide;

~~N-(3,5-dichloropyridin-4-yl)-[1-(2-chloro-6-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chloro-6-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chloro-6-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-difluoromethylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-cyanobenzyl)-7-azaindol-3-yl]glyoxylamide;

and physiologically tolerated salts thereof.

10-17 (canceled)

18. (previously presented) A drug product comprising a compound according to claim 1 and at least one of a conventional physiologically tolerated carrier, diluent or excipient.

19. (previously presented) A process for producing a drug product as claimed in claim 18, comprising admixing said compound with said carrier, diluent or excipient to form the drug product.

20. (previously presented) A pharmaceutical composition comprising a compound of claim 1 and at least one other active pharmaceutical agent.

21-26 (canceled)

27.(new) The compound of claim 1, wherein the heteroatom is (i) are N, O or S.

28.(new) The compound of claim 1, wherein the heteroatom in (ii) are N, O or S.

29.(new) The compound of claim 27, wherein the heteroatom in (ii) are N, O or S.